Trials / Completed
CompletedNCT02244333
Efficacy, Tolerability and Safety of ALNA® in Patients With Benign Prostatic Syndrome (BPS)
ALNA® - AWB in Pre-treated Patients With BPS
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 4,575 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Male
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Study to assess efficacy, tolerability and safety parameters of a one month ALNA® - treatment after switch from Terazosin-treatment
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALNA® |
Timeline
- Start date
- 2004-02-01
- Primary completion
- 2004-07-01
- First posted
- 2014-09-19
- Last updated
- 2014-09-19
Source: ClinicalTrials.gov record NCT02244333. Inclusion in this directory is not an endorsement.